wallet digital currency Top searches

Cao Guo, leader of South Korea's opposition party, the Motherland Reform Party, was sentenced to two years in prison. On the 12th local time, Cao Guo, leader of South Korea's opposition party, was sentenced to two years in prison and lost his parliamentary qualification. (CCTV News)The next "explosion point" of biomedicine may appear in Shenzhen. "China's pharmaceutical innovation ranks first in the second echelon in the world in terms of the quantitative indicators of R&D pipelines and listed new drugs." A few days ago, Song Ruilin, executive president of China Pharmaceutical Innovation Promotion Association, held the "Star of the Bay Area" biomedical source innovation conference in Shenzhen, and believed that China's pharmaceutical research and industrial development were entering a new stage of innovation. Chen Qiyu, vice president of China Pharmaceutical Innovation Promotion Association and executive director and co-CEO of Fosun International, said that Shenzhen has great advantages and development momentum in linking Greater Bay Area's urban development and AI technology. By leveraging the resources in the Bay Area and making good use of these advantages, it is possible to find a new fulcrum in the future biomedical R&D innovation track, and the next "explosion point" of biomedicine is likely to appear in Shenzhen.Genting Xinyao: The first prescription of itramod in Macau, China officially benefited Asian patients. Genting Xinyao announced that its first prescription of itramod was made in Jinghu Hospital in Macau, China on December 11th, which was the first prescription made by itramod after it was approved in Genting Xinyao Asia Authorized Zone, marking that this heavy product in the field of autoimmune diseases officially began to benefit Asian patients. Luo Yongqing, CEO of Genting Xinyao, said that the arrival of the first prescription of Ithmod in China and Macau was another milestone in the commercialization of Genting Xinyao. By 2030, the number of patients with ulcerative colitis in China is expected to more than double that in 2019, reaching about 1 million. There is a huge unmet demand for innovative therapies. Following the approval in Macau in April this year, Iturmod, as the third commercial new drug of Genting Xinyao, will bring new treatment options to more patients with ulcerative colitis.

The negative spread of 10-year national debt between China and the United States has expanded to nearly 250BP, which is the largest in more than 22 years.The securities sector fluctuated and strengthened, and the securities sector fluctuated and strengthened. Guosheng Financial Holdings had three consecutive boards, Guolian Securities rose more than 8%, and Harbin Investment Co., Ltd., Huaxin Co., Ltd., Cinda Securities and Southwest Securities followed suit.Xiong 'an Center of Beijing-Tianjin-Hebei National Technology Innovation Center officially started operation. On December 12th, Xiong 'an Center of Beijing-Tianjin-Hebei National Technology Innovation Center officially started operation, including the cooperation project of Xiong 'an Medical and Industrial Cross Transformation Research Institute of Peking University People's Hospital and the fourth generation semiconductor material doped AlN epitaxial wafer, and many independent innovative projects landed in xiong'an new area. As a national innovation platform, Xiong 'an Center will focus on key tasks such as building a first-class innovation platform, forming a composite innovation team, and improving the innovation and entrepreneurship ecology, and strive to create an important source of independent innovation and original innovation. (CCTV News)

Zou Yingguang, General Manager of CITIC Securities: It is expected that the demand for cross-border investment and financing at home and abroad will be further released. At the investor open day of CITIC Securities in 2024, Zou Yingguang, General Manager of CITIC Securities, said that the demand for two-way cross-border investment and financing is very strong, whether it is a China enterprise "going abroad" or an overseas investor "coming to China". Among them, with the rapid evolution of China's new open economic system, cross-border finance will usher in greater development space, and securities companies will be in cross-border finance. In the medium and long term, China's macro securitization rate is still accelerating, the internationalization of Chinese-funded enterprises will continue to increase, and the opening up of China's capital market will continue to increase. It is expected that the demand for cross-border investment and financing from domestic and foreign customers will be further released.Xiong 'an Center of Beijing-Tianjin-Hebei National Technology Innovation Center officially started operation. On December 12th, Xiong 'an Center of Beijing-Tianjin-Hebei National Technology Innovation Center officially started operation, including the cooperation project of Xiong 'an Medical and Industrial Cross Transformation Research Institute of Peking University People's Hospital and the fourth generation semiconductor material doped AlN epitaxial wafer, and many independent innovative projects landed in xiong'an new area. As a national innovation platform, Xiong 'an Center will focus on key tasks such as building a first-class innovation platform, forming a composite innovation team, and improving the innovation and entrepreneurship ecology, and strive to create an important source of independent innovation and original innovation. (CCTV News)The person in charge of public relations of Extreme Vietnam responded to the operating conditions, saying that the company had no money. Xu Jiye, the person in charge of public relations of Extreme Vietnam Automobile, responded to the financial difficulties of the company, saying that the company needed to find funds to survive because of lack of money. Xu Jiye stressed that he joined the company because he was optimistic about the products, and even bought one without receiving a salary, and recommended it to relatives and friends. He angrily refuted the remarks that the company's difficulties questioned the quality of products and said that he would continue to promote the cause of autonomous driving.